High folate receptor expression in gliomas can be detected
18F-labelled folate
PET
brain tumor
fluorine-18
folate receptor
glioma
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
01
2023
accepted:
28
04
2023
medline:
7
6
2023
pubmed:
5
6
2023
entrez:
5
6
2023
Statut:
epublish
Résumé
Non-invasive imaging techniques such as positron emission tomography (PET) are extremely important for cancer detection and characterization especially for difficult to biopsy or extremely delicate organs such as the brain. The folate analogue 1,4,7-triazacylononane-1,4,7-triacetic acid-conjugated folate radiolabeled with aluminum fluoride-18 ([ Nine BDIX rats were injected with BT4C rat glioma cells into the right hemisphere of the brain. Animals were imaged with gadolinium-enhanced magnetic resonance imaging at on days prior to PET/computed tomography (CT) imaging. Animals were divided into two groups, and were PET/CT imaged with either [ PET imaging showed an increase of [18F]FOL tumor-to-brain uptake ratio (TBR) over the study duration from day 16/19 (3.3 ± 0.9) increasing to 5.7 ± 1.0 by day 32. [ This study shows upregulation of FR-α inside glioma regions in both human and animal tissue, providing a biochemical basis for the observed increased [
Identifiants
pubmed: 37275898
doi: 10.3389/fimmu.2023.1145473
pmc: PMC10232737
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Folic Acid
935E97BOY8
Radiopharmaceuticals
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1145473Informations de copyright
Copyright © 2023 Miner, Liljenbäck, Virta, Kärnä, Viitanen, Elo, Gardberg, Teuho, Saipa, Rajander, Mansour, Cleveland, Low, Li and Roivainen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nucl Med Biol. 2014 Jul;41(6):457-63
pubmed: 24776091
Sci Rep. 2020 Jan 23;10(1):1047
pubmed: 31974480
Cancer Metastasis Rev. 2007 Mar;26(1):111-28
pubmed: 17334909
Biochim Biophys Acta. 1996 Jul 24;1312(3):237-42
pubmed: 8703993
Oncotarget. 2015 Oct 6;6(30):30327-33
pubmed: 26160847
Bioconjug Chem. 2012 Apr 18;23(4):805-13
pubmed: 22372827
Sci Rep. 2018 Jun 26;8(1):9720
pubmed: 29946129
Acta Oncol. 2014 Aug;53(8):1125-34
pubmed: 24957558
J Nucl Med. 2015 Oct;56(10):1562-8
pubmed: 26229144
Semin Cancer Biol. 2011 Apr;21(2):107-12
pubmed: 21167939
Ann Oncol. 2015 Oct;26(10):2034-43
pubmed: 26063635
Cancers (Basel). 2020 Jun 09;12(6):
pubmed: 32527010
ACS Omega. 2021 Feb 01;6(6):4111-4118
pubmed: 33623837
Mol Cancer Res. 2006 Apr;4(4):221-33
pubmed: 16603636
J Nucl Med. 2020 Nov;61(11):1643-1649
pubmed: 32284397
Anal Biochem. 2005 Mar 15;338(2):284-93
pubmed: 15745749
J Neuroinflammation. 2019 Dec 3;16(1):252
pubmed: 31796042
Oncotarget. 2016 Apr 5;7(14):17442-54
pubmed: 26943581
Molecules. 2020 Jun 25;25(12):
pubmed: 32630467
Front Cell Neurosci. 2017 Feb 13;11:24
pubmed: 28243193
Oncotarget. 2017 Dec 15;9(4):4485-4495
pubmed: 29435118
Congenit Anom (Kyoto). 2017 Sep;57(5):138-141
pubmed: 28603928
Nat Commun. 2013;4:2123
pubmed: 23828504
J Neurooncol. 2009 Sep;94(3):299-312
pubmed: 19381449
Clin Breast Cancer. 2017 Nov;17(7):544-549
pubmed: 28410844
Arch Immunol Ther Exp (Warsz). 2013 Feb;61(1):25-41
pubmed: 23224339
Arch Pathol Lab Med. 2014 Jul;138(7):890-5
pubmed: 24028341
Nat Rev Clin Oncol. 2020 Jun;17(6):349-359
pubmed: 32152484
Front Oncol. 2021 Oct 07;11:730358
pubmed: 34692505
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4325-4337
pubmed: 35838757
J Clin Oncol. 2023 May 1;41(13):2436-2445
pubmed: 36716407